As of June this year, based on Novanta's most recent financial report, the company's trailing twelve months EPS is $1.4. During 2025, NOVT reported a per-share earnings of $1.47, which shows a decline compared to the EPS of $1.78 recorded in 2024. Novanta's EPS for the quarterly period ending on Apr 3, 2026 came in at $0.52.
The yearly earnings per share during 2025 was $1.47, a decline of 17.4% compared to $1.78 recorded in 2024. Over the quarter ending Apr 3, 2026, the earnings per share came in at $0.52, reflecting a 11.9% decline compared to the same quarter a year earlier. As of April 2026, the TTM EPS is $1.4. During 2024, the annual earnings per share was $1.78, representing a decrease of 12.3% compared to 2023.
Novanta has recorded a decline in earnings per share of 11.9% in the past 12 months (YoY, quarterly). During the past three years, NOVT registered an average yearly EPS growth of -10.9%. Novanta had an average annual EPS growth of 3% in the last five years. Over the last decade, NOVT had an average annual earnings per share growth of 3.6%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| NOVT Novanta Inc | 118.04 | -17.4% | -10.9% | 3% |
| OBIO Orchestra BioMed Holdings Inc | N/A | 33.1% | N/A | N/A |
| OM Outset Medical Inc | N/A | 85.5% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.